Myriad Genetics some hours ago announced that it has acquired for $375m Counsyl, a company that develops and markets non-invasive screening systems to determine whether fetuses risk to develop genetic diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,